Rigel Pharmaceuticals Inc (RIGL) support and resistance · P/E 9.1, rev $179.3M
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
This page maps Rigel Pharmaceuticals Inc (RIGL) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new RIGL 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the RIGL quote page for the session range and the stock page for the full model.
Not investment advice.